Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
145.6 USD | -0.21% |
|
+0.17% | -7.08% |
06-17 | J&J: FDA application in lung cancer | CF |
06-17 | Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
1st Jan change | Capi. | |
---|---|---|
-7.08% | 351B | |
+52.93% | 803B | |
+41.27% | 631B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.77% | 243B | |
+2.17% | 228B | |
+10.35% | 217B | |
+6.24% | 164B | |
-4.79% | 155B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Johnson & Johnson Allegedly Engaged in 'Bad Faith' Bankruptcies That Harm Talc Victims, Lawsuit Says